한글목차

이 보고서는 미국과 유럽의 지불자의 관점에 초점을 맞추어 진화하는 암 치료제의 보험 적용 및 가격 책정 현황을 상세하게 분석합니다. 지불자의 의사결정에 영향을 미치는 주요 고려사항, 지불자 조직의 최근 변화의 영향, 바이오의약품 산업과의 관계의 역학관계를 살펴봅니다. 또한, 바이오시밀러의 역할, 임상 가이드라인의 영향, 업계 구조조정 및 정책 변화가 지불자의 의사결정에 미치는 잠재적 영향에 대해서도 살펴봅니다. 이 종합적인 분석은 암 분야의 약가 및 상환에 대한 풍부한 경험을 가진 전문가들과의 인터뷰를 기반으로 하고 있습니다.

보고서 내용

• 지불자가 암 치료제의 보험 적용 및 가격 결정 시 고려해야 할 사항들
• 최근의 변화가 암 치료제의 보험 적용 및 가격 책정에 대한 지불자의 사고방식에 어떤 영향을 미쳤는가?
• 암 치료제에 대한 지불자의 의사결정에 가장 큰 영향을 미치는 요인들
• 의사결정 과정을 개선하기 위해 지불자와 바이오제약 업계가 협력할 수 있는 방법
• 향후 암 분야에서 지불자의 의사결정에 영향을 미칠 수 있는 문제 및 동향은?
• 미국과 EU에서 암 치료제의 보험 적용에 대한 지불자의 접근 방식이 어떻게 다른가?

주요 기업

영문목차

This report provides an in-depth analysis of the evolving landscape of oncology drug coverage and pricing, focusing on the perspectives of payers in the US and EU. It explores the key considerations influencing payer decisions, the impact of recent changes within payer organisations and the dynamics of their relationships with the biopharmaceutical industry. Readers will gain insights into the strategies payers employ to manage costs, including the use of innovative payment methods and the challenges posed by rising drug prices. The report also examines the role of biosimilars, the influence of clinical guidelines and the potential effects of industry consolidation and policy changes on payer decision making. This comprehensive analysis is informed by interviews with experts who have extensive experience in oncology pricing and reimbursement.

Key Questions Answered:

• 1. What are the key considerations for payers when making coverage and pricing decisions for oncology drugs?
• 2. How have recent changes influenced payer thinking about oncology drug coverage and pricing?
• 3. What factors most heavily impact changes in payer decision making for oncology drugs?
• 4. How can payers and the biopharmaceutical industry collaborate to improve decision-making processes?
• 5. What issues and trends could influence future payer decision making in oncology?
• 6. How do payers' approaches to oncology drug coverage differ between the US and EU?

Key Companies:

Partial List of Participating Experts:

• Associate Director, Office of Health Economics, UK
• Senior clinical account executive at a leading pharmacy benefit manager, US
• President and CEO, Cooperative Benefits Group
• Specialty pharmacy co-founder and oncology leader at payers in the US
• Senior Healthcare Consultant at ADVI Health and former National Medical Director, Aetna, US
• Independent consultant and experienced managed care executive, based in the US
• Senior Vice President, Specialty, Real Endpoints, US
• Venture Partner at RA Capital Management and former EVP and CMO for Harvard Pilgrim Health Care and Point32Health, a regional not-for-profit health plan in the US

Methodology

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.